Ubac
ATC code
Species
Cattle.
Indications
For active immunisation of healthy cows and heifers to reduce the incidence of clinical intramammary infections caused by Streptococcus uberis, to reduce the somatic cell count in Streptococcus uberis positive quarter milk samples and to reduce milk production losses caused by Streptococcus uberis intramammary infections.
Onset of immunity: approximately 36 days after the second dose.
Duration of immunity: approximately the first 5 months of lactation.
Dose to be administered and administration route
Intramuscular use.
The injections should be preferably administered on the alternate sides of the neck. Allow the vaccine to reach a temperature of 15 °C to 25 °C before administration. Shake before use.
Administer one dose (2 ml) by deep intramuscular injection in the neck muscles according to the following immunisation program:
- First dose at approximately 60 days before the expected parturition date - Second dose at least 21 days before the expected parturition date - Third dose should be administered about 15 days after the calving.
Protection of animals not vaccinated following this program has not been demonstrated. This should be considered in case of herd vaccination.
The full immunisation program should be repeated with each gestation.
Adverse reactions
Cattle:
|
Very common (> 1 animal / 10 animals treated): |
Injection site swelling1 Elevated temperature2 |
|
Very rare (< 1 animal / 10 000 animals treated, including isolated reports): |
Anaphylactic -type reaction3 |
1 Local swelling more than 5 cm in diameter is very common after administration of the vaccine. This swelling will have disappeared or be clearly reduced in size by 17 days post vaccination. However, in some cases, swelling may persist for up to 4 weeks.
2 A transient increase in rectal temperature (mean increase of 1 °C but may be up to 2 °C in individual animals) may occur in the first 24 hours after injection.
3Anaphylactic-type reactions (e.g. oedema) which might be life-threatening, may occur in some sensitive animals. Under these circumstances, appropriate symptomatic treatment should be administered.
Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See the package leaflet for respective contact details.
TRUSTED SOURCE
